- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Impact of Personalized Medicine on Treatment Decisions
“We evaluate personalized medicine regimes that include lab testing, a scoring system, and other factors associated with the patient,” according to Edmund Pezalla, MD, MPH.
Pezalla explained that personalized medicine is evaluated based on whether the treatments have demonstrated better outcomes or if it is clear that they will alter clinical decisions. He emphasized that just an add-on test is of no value, so diagnostics that expect clinical integration should impact outcomes.
“Companion diagnostics are enormous in this area because they help make a choice for or against a drug and using it to choose a particular pathway. [These diagnostics] measure something that can be acted on,” Pezalla said.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
